ADHD

To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Researchers hope a new study will alleviate patients and clinicians fear of prescribing stimulants for children with ADHD.

In a recent study, positive safety and efficacy outcomes for serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH; Azstarys; KemPharm) were found in children aged 6 years and older with attention-deficit/hyperactivity disorder (ADHD).

A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.

A recent study found that while children exposed to benzodiazepine during pregnancy had a greater risk of developing autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), siblings without exposure saw similar risks of neurodevelopmental disorders.

Lisdexamfetamine dimesaylate was associated with reduced ADHD symptoms in children aged 4 to 5 years.

MRI studies have associated white matter bundles with greater severity of ADHD symptoms.

Teenagers with ADHD were less likely to engage in long glances away from the road after taking a computerized skills-training program, reducing the risk of collisions.

They also found no statistically significant associations found for specific cardiovascular outcomes in relation to cardiac arrest or arrhythmias, cerebrovascular diseases, or myocardial infarction.

The strongest confounders were family income, caregiver education, and ADHD polygenic risk scores for ADHD clinical range diagnoses.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, review specific risk factors of pediatric ADHD, focusing on family history.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, discuss the prevalence of pediatric ADHD and how diagnosis has spiked in recent years.

A recent review found that multiple clinical trials indicated a reduction in adult height potential for children with long-term use of stimulant medication for treatment of ADHD, but other studies conflict with this data.

In a recent study, children and adolescents with ADHD often had to change treatment in instances of ineffectiveness or complications.

In a recent study, pediatric patients with ADHD were less likely to be hospitalized from a mental disorder or need stimulant prescriptions when given general practitioner centered primary care.

A recent study independently associated maternal obesity with ADHD risk in offspring, with a significant risk observed in joint obesity and excessive weight gain.

In a recent study, children with ADHD were slower to reorient when looking at images of faces than children without ADHD.

ADHD has been linked with greater perceived stress and sleep problems in adolescents.

The results show pediatric patients with ADHD had a significantly higher risk of injuries requiring hospitalization compared to non-ADHD controls.

Older participants had smaller dual-task performance deficits for gait and texting speed in both the ADHD group and the control group.

A recent review suggests that atomoxetine can reduce symptoms of anxiety in children and adolescents with ADHD.

A recent study showed no correlation between prenatal exposure to triptans and diagnosis or symptoms of ADHD in children.

Investigators found that symptoms of attention-deficit/hyperactivity disorder were more often seen in children with a lower birth weight.

Treatments for ADHD proved to be the most effective in reducing the risks of developing substance use disorders.